Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar JorgeAura (21.19) Submitted: 12/6/2012 7:20:16 PM : Underperform Start Price: $1.13 PPHM Score: +18.46

Dead cat bounce. Bad management.

Featured Broker Partners


Advertisement